Crossmark

Real-world utility of platelet count, hemoglobin, and iron levels as predictors of clinical response to vedolizumab in patients with ulcerative colitis: a retrospective, single-center study in Poland

Crossref DOI link: https://doi.org/10.1186/s12876-026-04780-y

Published Online: 2026-04-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sobolewska-Włodarczyk, Aleksandra

Orliński, Jakub

Witas, Żaneta

Woźniak, Łukasz

Łysoń, Zuzanna

Gąsiorowska, Anita
License Information

Text and Data Mining valid from 2026-04-02

Version of Record valid from 2026-05-13
More Information

Article History

Received: 30 July 2025

Accepted: 25 March 2026

First Online: 2 April 2026

Declarations

:

: Studies that do not qualify as medical experiments, including retrospective analyses relying solely on previously collected clinical data, are exempt from the requirement of obtaining approval from a bioethics committee. Therefore, no approval was requested from the bioethics committee.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below